Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-01

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-

NCT02862366

Myeloproliferative Neoplasm

COMPLETED

Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

NCT05006677

Ventricular Thrombus

UNKNOWN

Long-term Surveillance of Patients With Venous Thromboembolism: a Nationwide Prospective Cohort Study

NCT06073366

Venous Thromboembolism

UNKNOWN

Value of D-dimer Combined With Other Thrombus Molecular Markers in Risk Assessment of VTE in Hospitalized Patients

NCT05515549

Venous Thromboembolic Disease

UNKNOWN

Gene-guided Warfarin for Anticoagulation Therapy

NCT04482842

Stroke

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Varices JAK2 Mutation Myeloproliferative Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anticoagulation group

Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.

Anticoagulation Agents

Intervention Type DRUG

Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.

Control group

Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anticoagulation Agents

Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged 18-75
* diagnosed as portal hypertension by contrast-enhanced computed tomography
* diagnosed as JAK2 positive

Exclusion Criteria

* not had portal contrast-enhanced computed tomography
* not had JAK2 mutation test
* other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No